Á¦1ȸ ¾È¿°Áõ ½ÉÆ÷Áö¾ö (Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ °øµ¿ÁÖ°ü) : 2022-11-13 |
|
Á¦1ȸ ¾È¿°Áõ ½ÉÆ÷Áö¾ö (Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ °øµ¿ÁÖ°ü) : 2022-11-13 ±³À°ÀÏÀÚ : 2022-11-13 ±³À°Àå¼Ò : ¼¿ï¼º¸ðº´¿ø ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : (¿Â-¿ÀÇÁº´Çà) Á¦1ȸ ¾È¿°Áõ ½ÉÆ÷Áö¾ö (Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ °øµ¿ÁÖ°ü) ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹Æ÷µµ¸·ÇÐȸ ´ã´çÀÚ : Á¶À翵 ¿¬¶ôó : 02-6403-4300 À̸ÞÀÏ : jyjomtl@naver.com ±³À°Á¾·ù : ¾È°ú Âü¼®¿¹»óÀοø : 400¸í Èñ¸ÁÆòÁ¡ : 5Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ ¼¼ºÎ¼ö°·á : 40,000¿ø ºñ°í Á¤È¸¿ø Àü¹®ÀÇ : »çÀüµî·Ï ¹«·á, ÇöÀåµî·Ï 40,000¿ø ºñȸ¿ø Àü¹®ÀÇ : »çÀüµî·Ï 30,000¿ø, ÇöÀåµî·Ï 40,000¿ø Àü°øÀÇ : »çÀüµî·Ï 20,000¿ø, ÇöÀåµî·Ï 30,000¿ø ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 08:50~08:55 °³È¸»ç ±è¼±¿õ(¿¬¼¼´ë) ±âŸ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 08:55~09:00 Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ ȸÀå´Ô ÀÎ»ç ¸»¾¸ ÇÔµ·ÀÏ ÀÌÇü±Ù(¼º±Õ°ü´ë ¿¬¼¼´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:00~09:10 A to Z essentials for ocular immunology ÃÖÇõÁø(¼¿ï´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:10~09:20 Innovative application of regenerative medicine for anterior segment inflammation management ³ª°æ¼±(°¡Å縯´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:20~09:30 Innovations in drug delivery and novel therapeutics for posterior segment inflammation management ¼ÛÁöÈÆ(¾ÆÁÖ´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:30~09:40 Ocular fluid biopsy in the omics era: anterior Áö¿ë¿ì(¿¬¼¼´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:40~09:50 Ocular fluid biopsy in the omics era: posterior ½ÅÁÖ¿µ(¼¿ï´ë) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:50~10:05 Discussion -(-) ÈÞ½Ä 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:05~10:20 Break -(-) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:20~10:30 Viral inflammatory diseases: anterior aspects ±è¼ºÀç(°æ»ó´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:30~10:40 Viral inflammatory diseases: posterior aspects Áö¿µ¼®(Àü³²´ë) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:40~10:45 Discussion -(-) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:45~10:55 Conjunctival melanoma ±è¼±¿õ(¿¬¼¼´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:55~11:05 Uveal melanoma À̽±Ô(¿¬¼¼´ë) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:05~11:10 Discussion -(-) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:10~11:20 Uveitis: anterior approach ¹Úö¿ë(µ¿±¹´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:20~11:30 Uveitis: posterior approach À̹̿¬(°¡Å縯´ë) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:30~11:35 Discussion -(-) ÈÞ½Ä 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:35~11:50 Break -(-) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:50~12:20 Demystifying Viral Anterior Uveitis Soon Phaik Chee(Singapore National Eye Centre) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:20~12:50 Treatment for Intermediate, Posterior and Panuveitis Jennifer Elizabeth Thorne(Johns Hopkins University) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:50~13:00 Discussion -(-) ½Ä»ç 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:00~14:00 Lunch -(-) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:00~14:10 Systemic work-up in uveitis patients; is it always necessary? ½ÅÁÖ¿¬(¿¬¼¼´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:10~14:20 Management of uveitis before and after cataract surgery Àü·ç¹Î(ÀÌÈ¿©´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:20~14:30 Surgical management of uveitis Á¶¿µÁØ(Ãæ³²´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:30~14:40 TASS vs endophthalmitis ±èÀç¿ë(¿ï»ê´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:40~14:50 How to approach inflammatory diseases in children ÀÌÁÖ¿ë(¿ï»ê´ë) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:50~15:05 Discussion -(-) ÈÞ½Ä 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:05~15:20 Break -(-) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:20~15:30 Outbreak of fungal endophthalmitis: the aftermath ±è¼º¿ì(°í·Á´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:30~15:40 The application of en face OCT imaging in uveitis ¸¶´ëÁß(ÇѸ²´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:40~15:50 Prevalence of HCQ Retinopathy and Recommendation on Screening in Rheumatic Patients with Dry Eye Symptoms Á¤Áö¿ø(ÀÎÇÏ´ë) ±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:50~16:00 The alternative faces of macrophage in the ocular surface ±è°æ¿ì(Áß¾Ó´ë) Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:00~16:10 Discussion -(-) ±âŸ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:10~16:15 Æóȸ»ç À̽±Ô(¿¬¼¼´ë) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|